Новости медицины

НПВП-ассоциированные язвы. Список литературы

Список литературы:

  1. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология 2015, 1:4-24.
  2. Zhou Y., Boudreau D.M., Freedman A.N. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiol Drug Saf 2014;23(1):43-50.
  3. Scarpignato C., Lanas A., Blandizzi C. et al. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis — an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Medicine 2015; 13:55. DOI: 10.1186/s12916-015-0285-8.
  4. Scheiman J. NSAID-induced Gastrointestinal Injury: A Focused Update for Clinicians. J Clin Gastroenterol 2016 Jan;50(1):5-10. doi: 10.1097/MCG.0000000000000432.
  5. Lanas Á. Hemorragia gastrointestinal. Gastroenterol Hepatol 2015 Sep;38 (Suppl 1):56-63. doi: 10.1016/ S0210-5705(15)30020-0.
  6. Del Piano M., Bianco M.A., Cipolletta L. et al. The «Prometeo» study: online collection of clinical data and outcome of Italian patients with acute nonvariceal upper gastrointestinal bleeding. J Clin Gastroenterol 2013 Apr;47(4): e33-7. doi: 10.1097/MCG.0b013e3182617dcc.
  7. Nagasue T., Nakamura S., Kochi S. et al. Time trends of the impact of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs on peptic ulcer bleeding in Japanese patients. Digestion 2015;91(1):37-41. doi: 10.1159/000368810. Epub 2015 Jan 20.
  8. Thomsen R., Riis A., Christensen S. et al. Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitors. Aliment Pharmacol Ther 2006;15;24(10):1431-8.
  9. Thomsen R., Riis A., Munk E. et al. 30-day mortality after peptic ulcer perforation among users of newer selective COX-2 inhibitors and traditional NSAIDs: a populationbased study. Am J Gastroenterol 2006;101(12):2704-10.
  10. Каратеев А.Е., Насонова В.А. Развитие и рецидивирование язв желудка и двенадцатиперстной кишки у больных, принимающих нестероидные противовоспалительные препараты. Тер арх 2008; 5:62-6.
  11. Маев И.В., Самсонов А.А., Андреев Д.Н. и др. Клиническое значение инфекции Helicobacter pylori. Клин мед 2013; 8:4-12.
  12. Pilotto A., Franceschi M. Helicobacter pylori infection in older people. World J Gastroenterol 2014 Jun 7; 20(21):6364-73. doi: 10.3748/wjg.v20.i21.6364.
  13. Testerman T.L., Morris J. Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. World J Gastroenterol 2014 Sep 28; 20(36):12781-808. doi: 10.3748/wjg.v20.i36.12781.
  14. Абдулхаков Р.А., Абдулхаков С.Р. Эпидемиология Helicobacter pylori. Практическая медицина 2006; 4(18):2-3.
  15. Герман С.В., Зыкова И.Е., Модестова А.В., Ермаков Н.В. Распространенность инфекции H. pylori среди населения Москвы. Рос журн гастроэнтерол гепатол колопроктол 2010; 2:25-30.
  16. Hunt R.H., Bazzoli F. Review article: should NSAID/ low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing. Aliment Pharmacol Ther 2004 Feb;19 (Suppl 1):9-16.
  17. Graham D.Y. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand. Am J Gastroenterol 1996; 91:2080-86
  18. Ивашкин В.Т., Лапина Т.Л. Эрадикационная терапия инфекции H. pylory при приеме нестероидных противовоспалительных средств. Рос журн гастроэнтерол гепатол колопроктол 2012; 6:15-9.
  19. Malfertheiner P., Chan F.K., McColl K.E. Peptic ulcer disease. Lancet 2009 Oct 24;374(9699):1449-61. doi: 10.1016/S0140-6736(09)60938-7. Epub 2009 Aug 13.
  20. Sostres C., Gargallo C.J., Lanas A. Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: Old question new insights. World J Gastroenterol 2014; 20(28):9439-50 DOI: http://dx.doi.org/10.3748/wjg. v20.i28.9439
  21. Huang J., Sridhar S., Hunt R. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359:14-22.
  22. Sostres C., Carrera-Lasfuentes P., Benito R. et al. Peptic Ulcer Bleeding Risk. The Role of Helicobacter pylori Infection in NSAID/Low-Dose Aspirin Users. Am J Gastroenterol 2015 May;110(5):684-9. doi: 10.1038/ ajg.2015.98. Epub 2015 Apr 21.
  23. Papatheodoridis G.V., Sougioultzis S., Archimandritis A.J. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin Gastroenterol Hepatol 2006 Feb;4(2):130-42.
  24. Santolaria S., Lanas A., Benito R. et al. Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users. Aliment Pharmacol Ther 1999; 13:1511-8.
  25. Kuyvenhoven J. P., Veenendaal R. A., Vandenbroucke J.P. Peptic ulcer bleeding: interaction between non-steroidal anti-inflammatory drugs, Helicobacter pylori infection, and the ABO blood group system. Scand J Gastroenterol 1999; 34:1082-6.
  26. Keilberg D., Ottemann K.M. How Helicobacter pylori senses, targets, and interacts with the gastric epithelium. Environ Microbiol 2016 Jan 15. doi: 10.1111/14622920.13222.
  27. Frezza M., Gorji N., Melato M. The histopatology of nonsteroidal anti-inflammatory drug induced gastroduodenal damage: correlation with Helicobacter pylori, ulcers, and hemorrhagic events. J Clin Pathol 2001; 54:521-5.
  28. Waldum H.L., Hauso Ø., Fossmark R. The regulation of gastric acid secretion — clinical perspectives. Acta Physiol (Oxf) 2014 Feb;210(2):239-56. doi: 10.1111/ apha.12208. Epub 2013 Dec 27.
  29. Schubert M.L. Gastric secretion. Curr Opin Gastroenterol 2014 Nov;30(6):578-82. doi: 10.1097/ MOG.0000000000000125.
  30. Sierra J.C., Hobbs S., Chaturvedi R. et al. Induction of COX-2 expression by Helicobacter pylori is mediated by activation of epidermal growth factor receptor in gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol 2013 Jul 15;305(2): G196-203. doi: 10.1152/ ajpgi.00495.2012. Epub 2013 May 16.
  31. Zhang Y., Pan K.F., Zhang L. et al. Helicobacter pylori, cyclooxygenase-2 and evolution of gastric lesions: results from an intervention trial in China. Carcinogenesis 2015 Dec;36(12):1572-9. doi: 10.1093/carcin/bgv147. Epub 2015 Oct 7.
  32. Shao Y., Sun K., Xu W. et al. Helicobacter pylori infection, gastrin and cyclooxygenase-2 in gastric carcinogenesis. World J Gastroenterol 2014 Sep 28;20(36):12860-73. doi: 10.3748/wjg.v20.i36.12860
  33. Hawkey C., Naesdal J., Wilson I. et al. Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesion in patients taking non-steroidal anti-inflammatory drugs. Gut 2002; 51:336-43.
  34. Boltin D., Halpern M., Levi Z. et al. Gastric mucin expression in Helicobacter pylori-related, nonsteroidal anti-inflammatory drug-related and idiopathic ulcers. World J Gastroenterol 2012 Sep 7;18(33):4597-603. doi: 10.3748/wjg.v18.i33.4597.
  35. Labenz J., Blum A., Bolten W. et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut 2002; 51:329-35.
  36. Lai K., Lau C., Ip W. et al. Effect of treatment of Helicobacter pylori on prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a doubleblind, placebo-controlled trial. Aliment Pharmacol Ther 2000; 17:799-805.
  37. Chan F., Sung J., Chung S. et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcer. Lancet 1997; 350:975-9
  38. Hawkey C.J., Yeomans N.D., Gillon K. Helicobacter pylori, NSAIDs, and peptic ulcers. Lancet 1998 Jan 3;351(9095):61; author reply 61-2.
  39. Vergara M., Catalán M., Gisbert J.P., Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005; 21(12):1411-8 [PMID:15948807 DOI: 10.1111/j.1365-2036.2005.02444.x]
  40. Tang C.L., Ye F., Liu W., Pan X.L., Qian J., Zhang G.X. Eradication of Helicobacter pylori infection reduces the incidence of peptic ulcer disease in patients using nonsteroidal anti-inflammatory drugs: a metaanalysis. Helicobacter 2012; 17:286-96 [PMID: 22759329 DOI: 10.1111/j.1523-5378.2012.00942.x].
  41. de Leest H.T., Steen K.S., Lems W.F. et al. Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial. Helicobacter 2007 Oct;12(5):477-85.
  42. Hawkey C., Tulassay Z., Szczepanski L. et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998 Sep 26;352(9133):1016-21.
  43. Каратеев А. Е., Муравьев Ю. В., РаденскаЛоповок С.Г., Насонова В.А. Эффективность антигеликобактерной терапии при НПВП-индуцированной гастропатии. Клин мед 2003; 4:37-41.
  44. Chan F.K., Chung S.C., Suen B.Y. et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344:967-3 [PMID: 11274623 DOI: 10.1056/NEJM200103293441304]
  45. Chan F.K., Ching J.Y., Suen B.Y. et al. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology 2013 Mar;144(3):528-35. doi: 10.1053/j. gastro.2012.12.038. Epub 2013 Jan 16.
  46. Malfertheiner P., Megraud F., O’Morain C. et al. Management of Helicobacter pylori infection — the Maastricht IV / Florence Consensus Report. Gut 2012; 61:646-64. doi:10.1136/gutjnl-2012-302084.
  47. Simon L., Weaver A., Graham D. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized control trial. JAMA 1999; 282:1921-8.
  48. Emery P., Zeidler H., Kvien T. et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison. Lancet 1999; 354:2106-11.
  49. Hunt R., Harper S., Callegari P. et al. Complementary studies of the gastrointestinal safety of the cyclooxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther 2003; 17:201-10. doi: 10.1046/j.02692813.2003.01407.x.
  50. Goldstein J., Hochberg M., Fort J. et al. Clinical trial: the incidence of NSAID-associated en-doscopic gastric ulcers in patients treated with PN400 (naproxen plus esomeprazole mag-nesium) vs. enteric-coated naproxen alone. Aliment Pharmacol Ther 2010; 32(3):401-13.
  51. Laine L., Kivitz A., Belo A. et al. Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers. Am J Gastroenterol 2012; 107:37986.
  52. Cryer B., Li C., Simon L. et al. GI-REASONS: A Novel 6-Month, Prospective, Randomized, Open-Label, Blinded Endpoint (PROBE) Trial. Am J Gastroenterol 2012; 108(3):392-400.
  53. Venerito M., Malfertheiner P. Interaction of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in gastric and duodenal ulcers. Helicobacter 2010 Aug; 15(4):239-50. doi: 10.1111/j.1523-5378.2010.00762.x.
  54. Lim Y.J., Hong S.J. Helicobacter pylori infection in nonsteroidal anti-inflammatory drug users. Korean J Gastroenterol 2014 Aug;64(2):70-5.
  55. Ghotaslou R., Leylabadlo H.E., Asl Y.M. Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review. World J Methodol 2015 Sep 26;5(3):164-74. doi: 10.5662/wjm.v5.i3.164. eCollection 2015.
  56. Маев И.В., Кучерявый Ю.А., Андреев Д.Н. Антибиотикорезистентность Helicobacter pylori: от клинического значения до молекулярных механизмов. Лечащий врач 2014; 2:34-40.
  57. Маев И.В., Вьюгнова Е.С., Петрова Е.Г. Побочные действия современной антигеликобактерной терапии. Клин мед 2002; 6:7-12.
Теги

Комментировать

Нажмите для комментария

Мы на Facebook